JP2022509206A5 - - Google Patents

Info

Publication number
JP2022509206A5
JP2022509206A5 JP2021529827A JP2021529827A JP2022509206A5 JP 2022509206 A5 JP2022509206 A5 JP 2022509206A5 JP 2021529827 A JP2021529827 A JP 2021529827A JP 2021529827 A JP2021529827 A JP 2021529827A JP 2022509206 A5 JP2022509206 A5 JP 2022509206A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutical composition
composition according
pain
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063451 external-priority patent/WO2020112905A1/en
Publication of JP2022509206A publication Critical patent/JP2022509206A/ja
Publication of JP2022509206A5 publication Critical patent/JP2022509206A5/ja
Pending legal-status Critical Current

Links

JP2021529827A 2018-11-28 2019-11-26 Magl阻害剤による疾病の治療方法 Pending JP2022509206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772554P 2018-11-28 2018-11-28
US62/772,554 2018-11-28
PCT/US2019/063451 WO2020112905A1 (en) 2018-11-28 2019-11-26 Methods of treating disease with magl inhibitors

Publications (2)

Publication Number Publication Date
JP2022509206A JP2022509206A (ja) 2022-01-20
JP2022509206A5 true JP2022509206A5 (cg-RX-API-DMAC7.html) 2022-11-28

Family

ID=70851863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529827A Pending JP2022509206A (ja) 2018-11-28 2019-11-26 Magl阻害剤による疾病の治療方法

Country Status (15)

Country Link
US (1) US20220031676A1 (cg-RX-API-DMAC7.html)
EP (1) EP3886844A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022509206A (cg-RX-API-DMAC7.html)
KR (1) KR20210097734A (cg-RX-API-DMAC7.html)
CN (1) CN113347971A (cg-RX-API-DMAC7.html)
AU (1) AU2019389017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015043A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120577A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001363A1 (cg-RX-API-DMAC7.html)
IL (1) IL283508A (cg-RX-API-DMAC7.html)
MA (1) MA54313A (cg-RX-API-DMAC7.html)
MX (1) MX2021006312A (cg-RX-API-DMAC7.html)
SG (1) SG11202105320YA (cg-RX-API-DMAC7.html)
WO (1) WO2020112905A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103975B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200738A (en) 2017-05-23 2024-01-13 H Lundbeck As Pyrazole magl inhibitors
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
KR20230142745A (ko) 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Cdk2抑制劑及其使用方法
AU2022318349B2 (en) 2021-07-30 2025-12-18 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
CA3234430A1 (en) * 2021-11-02 2023-05-11 Samuel George ANDREW Crystalline forms of a monoacylglycerol lipase inhibitor
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010239188B2 (en) * 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10570146B2 (en) * 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
WO2017087858A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10519134B2 (en) * 2015-11-20 2019-12-31 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
KR20170128029A (ko) * 2016-05-13 2017-11-22 삼성에스디아이 주식회사 태양전지 전극 형성용 조성물 및 이로부터 제조된 전극
JP2020506903A (ja) * 2017-01-23 2020-03-05 ファイザー・インク Magl阻害薬としての複素環式スピロ化合物
MY200738A (en) * 2017-05-23 2024-01-13 H Lundbeck As Pyrazole magl inhibitors
US10927105B1 (en) * 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors

Similar Documents

Publication Publication Date Title
US20260098036A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
JP6964096B2 (ja) 3−オキソ−2,6−ジフェニル−2,3−ジヒドロピリダジン−4−カルボキサミド類
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2020521767A5 (cg-RX-API-DMAC7.html)
US11591311B2 (en) 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
EP3713926B1 (en) 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
AU2018255300A1 (en) Bicyclic compounds and their use in the treatment of cancer
WO2019101642A1 (en) Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US11524944B2 (en) 2-phenylpyrimidine-4-carboxamides as AHR inhibitors
JP2019512505A5 (cg-RX-API-DMAC7.html)
CN118843630A (zh) 作为pkmyt1抑制剂的杂芳族化合物及其用途
RU2013114771A (ru) Диамиды азетидинила как ингибиторы моноацилглицерол липазы
RU2015115400A (ru) Гетероароматические соединения и их применение в качестве допаминовых D1 лигантов
JP2024516033A5 (cg-RX-API-DMAC7.html)
WO2019090082A1 (en) Modulators of the integrated stress pathway
WO2018210729A1 (en) Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor
EA036318B1 (ru) 6-аминопиридин-3-илтиазолы в качестве модуляторов rort
JP2022530322A5 (cg-RX-API-DMAC7.html)
JP2015502371A5 (cg-RX-API-DMAC7.html)
RU2019109570A (ru) 8-(азетидин-1-ил)-[1,2,4]триазоло[1,5-а]пиридинилы, композиции и способы их применения
JP2024538602A5 (cg-RX-API-DMAC7.html)
TW201920202A (zh) 吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑
JP6169699B2 (ja) 脆弱x症候群、パーキンソン病又は逆流性疾患の治療に有用なジアゼピノン誘導体
RU2021113744A (ru) Способы лечения заболевания с использованием ингибиторов magl
NZ790187B2 (en) C7, C12, and C16 substituted neuroactive steroids and their methods of use